Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis - Anaissie, EJ; Coleman, EA; Goodwin, JA (Cancer, 2012)
et al.